September 2025 Issue

Journey alongside Pharmaron as we embrace the latest advancements to fast-track the discovery and development of small molecules and emerging modalities.

Stay informed with Pharmaron’s latest updates, including molecular glue discovery, our ocular model portfolio, how we decode omics data, our approach to integrating in vitro and in vivo ADME, and more.

Drug Discovery

Discovery of Molecular Glues: Concepts, Case Studies, and Future Technologies

Our scientists are at the forefront of molecular glue discovery. Join our two-part webinar series to explore advancements in targeted protein degradation and innovative drug discovery techniques.

• Gain insights from case studies on degrader discovery.
• Explore novel hit-finding assays and approaches.
• Learn about chemical strategies driving early hits to clinical candidates.
• Discover future perspectives and emerging technologies in the field.

Watch Part 1 On-Demand →

Register for Part 2 of the Webinar on Sept 25 →

Safety Assessment

Ocular Toxicology and Preclinical Readiness

The eye is one of the most sensitive and complex organs in the body—and even small toxicological effects can have a profound impact. With over a decade of experience, our team utilizes cutting-edge tools and techniques to assess critical endpoints, guided by ACVO and DABT toxicologists.

From state-of-the-art imaging systems like OCT and fundus photography, to custom disease models for glaucoma, diabetic retinopathy, and inherited retinal disorders, our resources ensure precision in every study.

Explore our ocular toxicology & safety assessment expertise →

in vivo Pharmacology

Discover our Inflammation, Immunology & Pain Animal Models

Our expert teams, specializing in disease-specific research, have developed an extensive portfolio of animal disease models designed for reproducible and translational outcomes.

• Transgenic models enable human antibody testing and precise targeting of disease pathways.
• Flexible induction methods mimic diverse disease mechanisms.
• Integrated biomarker, PK/PD, and pathology services accelerate discovery timelines.

Explore our disease model portfolio →

NEWS

in vitro Biology

PharmaRonNet: Decoding Omics Data

Utilize our bioinformatics tool to rescue your negative omics data by inferring causal gene interaction networks to overcome biological noise and technical losses in high-throughput omics studies.

View the full poster →

Radiolabeled Sciences

Accelerator Mass Spectrometry in hADME

Accelerator Mass Spectrometry transforms the way human ADME studies are conducted. Join our on-demand webinar to learn about recent and future advances of this highly sensitive approach to pharmacokinetic research.

Watch our webinar →

Medicinal Chemistry

Discovery of a Pan-Coronavirus 3CLpro Inhibitor

Our chemistry team has proudly supported Aligos Therapeutics in the discovery of ALG-097558, an orally available SARS-CoV-2 inhibitor which demonstrates efficacy across coronaviruses.

Read the full publication →

INSIDE PHARMARON

DMPK

Our Integrated Approach to and in vivo ADME: Smarter, Seamless Decision-Making

Pharmaron's integrated ADME platform combines in vitro and in vivo data to provide a comprehensive view of your compounds’ pharmacokinetic profile by supporting confident decision-making from lead optimization through to candidate selection. Our scientists work across disciplines to ensure faster data delivery, consistent interpretation, and better alignment with your development goals.

• Do you require early insights into clearance, bioavailability, and tissue exposure?
• Want harmonized study design and data integration?
• Need customizable packages to match your program stage?

Learn more and find out how we can help you achieve your goals →

PODCASTS

DMPK

The Influence of QSAR and Physicochemical Descriptors on Drug Design

Join Dr. Matt Segall, CEO of Optibrium, as he explores how QSAR and physicochemical descriptors revolutionize drug design, improving ADME properties and shaping the future of computational ADME science.

Listen to this new episode of our DMPK Insights Podcast now →

DMPK

Evolution of CNS Drug Disposition Models

Join Dr. Matt Segall, CEO of Optibrium, as he explores how QSAR and physicochemical descriptors revJoin our guest speaker Prof. Elizabeth de Lange from Leiden University to explore how PBPK models deepen our understanding of CNS drug distribution, predict human pharmacokinetics, and advance translational research across species.

Listen to our new podcast about CNS drug disposition models →

UPCOMING

DMPK and Radiolabeled Sciences

Join us at the ISSX Conference in Chicago

Sept 21-24, Chicago, IL, US

Join Pharmaron at Booth #307, where our team will showcase cutting-edge DMPK and radiolabeling expertise supporting drug development from discovery to clinic. Don’t miss our lineup of scientific posters covering topics from mass balance studies to BBB permeability and RIS.

Schedule a meeting to connect with our experts and explore how we can help advance your ADME insights into meaningful impact →

Drug Discovery

Meet us at the ELRIG Conference in Liverpool

Oct 21-22, Liverpool, UK. Booth #C20.

Join us at ELRIG to connect with our scientists—Chris Wellaway, Delia Brustur, Omar Loss, and more—and discover our latest innovations in drug discovery:

• Our Direct-to-Biology approach to test unpurified compounds to accelerate protein degrader discovery
• in vitro testing of inhibitors targeting two domains of DNA polymerase theta
• The enhancement of our fragment library with novel chemical functionalities

Don’t miss your chance - schedule a meeting with our team to explore how we can collaborate.

Follow Us on LinkedIn. Find us on X. Visit our Website.